{"entity":{"id":"ye-dingwei","kind":"person","name":"Dingwei Ye","aka":[],"tldr":"Dingwei Ye is China's leading uro-oncologist, whose department runs the Chinese arms of major prostate and bladder cancer trials.","summary":"Dingwei Ye is Professor and Chair of the Department of Urology at Fudan University Shanghai Cancer Center. He is China's leading uro-oncologist, and his department runs the Chinese arms of major prostate and bladder cancer trials, including studies of androgen receptor pathway inhibitors such as enzalutamide, PARP inhibitors, and the antibody-drug conjugates enfortumab vedotin and disitamab vedotin in urothelial cancer. His publications include trials of abiraterone plus prednisone and of apalutamide in metastatic castration-sensitive prostate cancer, including the LATITUDE study. His interests span prostate, bladder and kidney cancer and urologic surgery.","asOf":"2026-09-08","links":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ye%20D%5BAuthor%5D%20Fudan%20prostate%20urology"}],"tags":[],"related":[],"cancers":["prostate","urothelial","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["disitamab-vedotin","enzalutamide"],"companies":[],"institutions":["fuscc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Chair, Department of Urology, Fudan University Shanghai Cancer Center","institutionId":"fuscc","specialisms":["Prostate cancer","Bladder cancer","Kidney cancer","Urologic surgery"],"profiles":[{"label":"Fudan University Shanghai Cancer Center","url":"https://www.shca.org.cn"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ye%20D%5BAuthor%5D%20Fudan%20prostate%20urology"}],"papers":[{"title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","journal":"New England Journal of Medicine","year":2017,"doi":"10.1056/nejmoa1704174"},{"title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","journal":"New England Journal of Medicine","year":2019,"doi":"10.1056/nejmoa1903307"},{"title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","journal":"The Lancet Oncology","year":2019,"doi":"10.1016/s1470-2045(19)30082-8"}]},"route":"/people/ye-dingwei/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"}],"institution":[{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/"}]}}